Literature DB >> 20362332

Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.

Kamal K S Abbi, Syed M Rizvi, Jeffrey Sivik, Subramanian Thyagarajan, Thomas Loughran, Joseph J Drabick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20362332     DOI： 10.1016/j.leukres.2010.02.036

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  6 in total

1.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 2.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

3.  Declining Guillain-Barré syndrome after campylobacteriosis control, New Zealand, 1988-2010.

Authors:  Michael G Baker; Amanda Kvalsvig; Jane Zhang; Rob Lake; Ann Sears; Nick Wilson
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

4.  Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.

Authors:  Marieke van der Zwan; Carla C Baan; Teun van Gelder; Dennis A Hesselink
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

Review 5.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

Review 6.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.